Earnings Call Summary | Karyopharm Therapeutics(KPTI.US) Q2 2024 Earnings Conference
With 58% Ownership, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Boasts of Strong Institutional Backing
Results: Karyopharm Therapeutics Inc. Confounded Analyst Expectations With A Surprise Profit
Karyopharm Therapeutics: A Cautious Hold Amid Steady Performance and Pipeline Uncertainties
Express News | HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target
Express News | Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $5
Karyopharm Therapeutics (KPTI) Gets a Buy From RBC Capital
Buy Rating Affirmed for Karyopharm Therapeutics Amid Strong Q2 Performance and Positive Xpovio Sales Outlook
Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5
Q2 2024 Karyopharm Therapeutics Inc Earnings Call
Express News | Karyopharm Therapeutics Inc : Jefferies Cuts Target Price to $4.50 From $5.50
Karyopharm Therapeutics | 10-Q: Q2 2024 Earnings Report
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q2 Revenue $42.8M, Vs. Street Est of $36.2M
Express News | Karyopharm Revises FY24 Total Revenue Outlook From $140M - $160M To $145M - $160M, Est $145.44M
Karyopharm Therapeutics Q2 2024 GAAP EPS $(0.20) Beats $(0.30) Estimate, Sales $42.786M Beat $36.179M Estimate
Express News | Karyopharm Therapeutics Q2 Product Revenue USD 28.032 Million
Express News | Karyopharm Therapeutics Q2 Operating Income USD -28.12 Million
Express News | Karyopharm Therapeutics Q2 Operating Expenses USD 70.906 Million
Express News | Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Express News | Karyopharm Therapeutics Q2 Net Income USD 23.792 Million